LRMR — Larimar Therapeutics, Inc.

Summary of Larimar Therapeutics Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Larimar reported pro forma cash of $203.6 million as of June 30, 2025, providing a runway into Q4 2026 following a recent capital raise.

2. Strategic Updates and Business Highlights

• Nomlabofusp Development: The company presented positive data from an ongoing long-term open-label study of nomlabofusp for Friedreich's ataxia (FA). Key findings include:
  • Clinical Improvements: Participants showed a median improvement of 2.25 points in the modified Friedreich's ataxia rating scale (mFARS) after one year, compared to a worsening of 1 point in a reference population from the FACOMS natural history study.
  • Frataxin Levels: 100% of participants achieved skin frataxin levels greater than 50% of those found in healthy volunteers after 6 months.
  • Safety Profile: Nomlabofusp was generally well tolerated, with mild to moderate injection site reactions being the most common adverse events. However, there were 7 reported cases of anaphylaxis, primarily occurring in patients with prior drug exposure.

3. Forward Guidance and Outlook

• BLA Submission: Larimar is targeting a Biologics License Application (BLA) submission in Q2 2026, seeking accelerated approval based on skin frataxin levels as a surrogate endpoint.
• Global Phase III Study: The company is qualifying sites for a global Phase III study, which will include 100-150 ambulatory patients aged 2-40, with a focus on younger patients.

4. Bad News, Challenges, or Points of Concern

• Anaphylaxis Events: The occurrence of anaphylaxis in 7 patients raised safety concerns, leading to a modification of the dosing regimen to include a test dose and antihistamines prior to administration. The company is monitoring the situation closely but acknowledges the risk of allergic reactions.
• Patient Population: The study population primarily consisted of patients with advanced disease, which may complicate the interpretation of efficacy data in younger, ambulatory patients expected in the Phase III trial.

5. Notable Q&A Insights

• Efficacy vs. Historical Controls: Management emphasized that comparisons should be made at the one-year mark due to the annual data collection of the FACOMS study. They expressed confidence in the compelling nature of their data.
• Safety Management: The company is implementing a new dosing strategy to mitigate anaphylaxis risks, which includes a 5-milligram test dose followed by a higher dose after observation.
• Regulatory Engagement: The FDA has been supportive, agreeing to the new dosing regimen without requiring additional safety follow-up data. Management remains optimistic about the BLA submission timeline despite safety concerns.

Overall, Larimar Therapeutics is making significant progress in its nomlabofusp program for Friedreich's ataxia, with promising clinical data and a clear path toward regulatory submission, albeit with notable safety challenges that the company is actively addressing.